127 related articles for article (PubMed ID: 18181342)
21. Docetaxel consolidation therapy following cisplatin, vinorelbine, and concurrent thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer.
Sekine I; Nokihara H; Sumi M; Saijo N; Nishiwaki Y; Ishikura S; Mori K; Tsukiyama I; Tamura T
J Thorac Oncol; 2006 Oct; 1(8):810-5. PubMed ID: 17409964
[TBL] [Abstract][Full Text] [Related]
22. Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial.
Pectasides D; Pectasides M; Farmakis D; Kostopoulou V; Nikolaou M; Gaglia A; Koumpou M; Mylonakis N; Xiros N; Economopoulos T; Raptis SA
Ann Oncol; 2005 Feb; 16(2):294-9. PubMed ID: 15668287
[TBL] [Abstract][Full Text] [Related]
23. A phase II study of weekly docetaxel-cisplatin as first-line treatment for advanced non-small cell lung cancer.
Binder D; Hackenthal M; Graseck L; Schweisfurth H; Schäper C; Krüll M; Temmesfeld-Wollbrück B; Suttorp N; Beinert T; Hellriegel KP
J Thorac Oncol; 2009 Sep; 4(9):1144-7. PubMed ID: 19609222
[TBL] [Abstract][Full Text] [Related]
24. A phase II study of irinotecan plus cisplatin for patients with advanced stage IIIB or IV NSCLC previously treated with nonplatinum-based chemotherapy.
Kim HT; Han JY; Lee DH; Chun JH; Lee HG; Lee JJ; Kim HY; Lee SY; Lee JS
Cancer; 2006 Aug; 107(4):799-805. PubMed ID: 16826586
[TBL] [Abstract][Full Text] [Related]
25. Doublet regimen of cisplatin plus docetaxel for second-line chemotherapy after prior therapy with cisplatin plus irinotecan for non-small cell lung cancer: a phase II study.
Seto T; Takezako Y; Nakamura H; Takeda K; Inoue F; Semba H; Eguchi K
Int J Clin Oncol; 2004 Oct; 9(5):378-82. PubMed ID: 15549588
[TBL] [Abstract][Full Text] [Related]
26. Docetaxel and cisplatin as induction chemotherapy in patients with pathologically-proven stage IIIA N2 non-small cell lung cancer: a phase II study of the European organization for research and treatment of cancer (EORTC 08984).
Biesma B; Manegold C; Smit HJ; Willems L; Legrand C; Passioukov A; van Meerbeeck JP; Giaccone G;
Eur J Cancer; 2006 Jul; 42(10):1399-406. PubMed ID: 16759850
[TBL] [Abstract][Full Text] [Related]
27. Phase II study of 3-week scheduling of irinotecan in combination with cisplatin in patients with advanced nonsmall-cell lung cancer.
Saito H; Kudoh S; Nakagawa K; Negoro S; Matsui K; Semba H; Takada M
Am J Clin Oncol; 2006 Oct; 29(5):503-7. PubMed ID: 17023787
[TBL] [Abstract][Full Text] [Related]
28. Phase II study of biweekly administration of docetaxel and irinotecan in patients with refractory or relapsed advanced non-small cell lung cancer.
Hirose T; Shirai T; Ishida H; Ando K; Sugiyama T; Kusumoto S; Hosaka T; Nakashima M; Ohmori T; Adachi M
Cancer Chemother Pharmacol; 2007 Jul; 60(2):267-74. PubMed ID: 17273827
[TBL] [Abstract][Full Text] [Related]
29. Combination chemotherapy with irinotecan and cisplatin in elderly patients (>or= 65 years) with extensive-disease small-cell lung cancer.
Kim HG; Lee GW; Kang JH; Kang MH; Hwang IG; Kim SH; Hahm JR; Jeong YY; Kim HC; Lee JD; Lee JS; Hwang YS
Lung Cancer; 2008 Aug; 61(2):220-6. PubMed ID: 18272249
[TBL] [Abstract][Full Text] [Related]
30. Phase II study of docetaxel and cisplatin administered as three consecutive weekly infusions for advanced non-small cell lung cancer.
Niho S; Ohe Y; Kakinuma R; Kubota K; Matsumoto T; Ohmatsu H; Goto K; Nishiwaki Y
Lung Cancer; 2002 Feb; 35(2):209-14. PubMed ID: 11804695
[TBL] [Abstract][Full Text] [Related]
31. Randomised phase II study of docetaxel/cisplatin vs docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group Study (WJTOG9803).
Yamamoto N; Fukuoka M; Negoro SI; Nakagawa K; Saito H; Matsui K; Kawahara M; Senba H; Takada Y; Kudoh S; Nakano T; Katakami N; Sugiura T; Hoso T; Ariyoshi Y
Br J Cancer; 2004 Jan; 90(1):87-92. PubMed ID: 14710212
[TBL] [Abstract][Full Text] [Related]
32. A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC).
Raez LE; Santos ES; Webb RT; Wade J; Brito RA; Karr M; Kennah A; Childs BH
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1103-10. PubMed ID: 24057043
[TBL] [Abstract][Full Text] [Related]
33. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
Han JY; Cho KH; Lee DH; Kim HY; Kim EA; Lee SY; Lee JS
J Clin Oncol; 2005 May; 23(15):3488-94. PubMed ID: 15908658
[TBL] [Abstract][Full Text] [Related]
34. Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma.
Socinski MA; Sandler AB; Israel VK; Gillenwater HH; Miller LL; Locker PK; Antonellini A; Elfring GL; Natale RB
Cancer; 2002 Oct; 95(7):1520-7. PubMed ID: 12237921
[TBL] [Abstract][Full Text] [Related]
35. Overview of docetaxel (Taxotere)/cisplatin combination in non-small cell lung cancer.
Le Chevalier T; Bérille J; Zalcberg JR; Millward MJ; Monnier A; Douillard JY; McKeage MJ; James R; Soulas F; Loret C; Bougon N; Bizzari JP
Semin Oncol; 1999 Jun; 26(3 Suppl 11):13-8. PubMed ID: 10458205
[TBL] [Abstract][Full Text] [Related]
36. Phase II study of weekly docetaxel combined with cisplatin in patients with advanced non-small-cell lung cancer.
Tsunoda T; Koizumi T; Hayasaka M; Hirai K; Koyama S; Takabayashi Y; Fujimoto K; Kubo K
Cancer Chemother Pharmacol; 2004 Aug; 54(2):173-7. PubMed ID: 15127230
[TBL] [Abstract][Full Text] [Related]
37. Biweekly docetaxel-irinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A phase I study.
Frasci G; Comella P; Thomas R; Di Bonito M; Lapenta L; Capasso I; Botti G; Vallone P; De Rosa V; D'Aiuto G; Comella G
Cancer Chemother Pharmacol; 2004 Jan; 53(1):25-32. PubMed ID: 14513281
[TBL] [Abstract][Full Text] [Related]
38. Phase II study of irinotecan and docetaxel in patients with previously treated non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 007).
Grossi F; Fasola G; Rossetto C; Spizzo R; Meduri S; Sibau A; Vigevani E; Tumolo S; Adami G; Sacco C; Recchia L; Rizzato S; Ceschia T; Belvedere O
Lung Cancer; 2006 Apr; 52(1):89-92. PubMed ID: 16483688
[TBL] [Abstract][Full Text] [Related]
39. A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer.
Tabata M; Kiura K; Okimoto N; Segawa Y; Shinkai T; Yonei T; Kuyama S; Harita S; Hotta K; Ueoka H; Tanimoto M
Cancer Chemother Pharmacol; 2007 Jun; 60(1):1-6. PubMed ID: 17393168
[TBL] [Abstract][Full Text] [Related]
40. Phase I and pharmacokinetic study of docetaxel, irinotecan, and celecoxib in patients with advanced non-small cell lung cancer.
Argiris A; Kut V; Luong L; Avram MJ
Invest New Drugs; 2006 May; 24(3):203-12. PubMed ID: 16096702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
